Michael John Morser - San Francisco CA
Mariko Nagashima - Belmont CA
Schering Aktiengesellschaft - Berlin
It is a general object of the present invention to provide compositions that specifically interact with advanced glycosylation end products (AGEs) or their receptors. Such compositions may be used in a variety of applications including therapeutic applications, e. g. , as blocking agents to inhibit or otherwise reduce the AGE/RAGE interaction, screening applications, e. g. , as models of the AGE/RAGE interaction, and diagnostic applications, e. g. , to identify abnormal levels of AGE or RAGE in a given system.